Tanja Aarvak
Director, Program Management, Alpha Radioligand Therapy ARTBIO
Dr. Tanja Aarvak is Director of Portfolio and Program Management at ARTBIO, where she is responsible for leading and overseeing development programs in Pb-212 targeted radiopharmaceuticals. She brings more than a decade of experience in radioligand therapy, spanning preclinical translation, early-phase clinical development, and registration-oriented activities. Her expertise includes program strategy, cross-functional portfolio execution across scientific, clinical, CMC, regulatory, and operational functions as well as the advancement of targeted alpha therapy platforms. Dr. Aarvak combines scientific insight with operational leadership to support the translation of innovative radiopharmaceutical approaches into clinically meaningful therapeutic opportunities for patients.
Seminars
- Sharing the development journey of AB001 from discovery and preclinical development through Phase 0 and into Phase I clinical evaluation
- Exploring the clinical, regulatory and CMC considerations required to successfully transition alpha radioligand therapies into the clinic
- Evaluating the manufacturing and supply challenges associated with short-lived radionuclides, including the implications of a 10.5-hour half-life on clinical execution
